Fierce Biotech regularly pulls together the industry’s top money raisers from the year before. Staff writer Gabrielle Masson and Editor-in-Chief Ayla Ellison discuss a few of the biotechs at the top of the list.
Plus, in this episode, we cover Johnson & Johnson's talc litigation, prison plans for Elizabeth Holmes and more of this week's top headlines.
To learn more about the topics in this episode:
The Top Line is produced by senior podcast producer Teresa Carey and managing editor Querida Anderson. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.
See omnystudio.com/listener for privacy information.
A cell therapy reckoning
Automation, decentralization and the future of CAR-Ts: Advancements in cell & gene therapy manufacturing (Part III)
[Sponsored] Opportunities & Challenges of Digital Pathology Adoption in CDx Development
[Sponsored] Unlocking health equity: The promise of digital health technologies
Advancements in cell & gene therapy manufacturing (Part II)
Fulfilling the promise of cell & gene therapies through manufacturing (Part I)
A closer look at 2023's top biopharma deals and what lies ahead
A look at pharma revenue rankings
Winning formulas for the best biotech and drug names
[Sponsored] What does the future of specialist distribution look like?
Deep dive: Biopharma layoffs in Q1
The unrecognized threat of PAD
The top money raisers in biotech
A closer look at European biotech investment in 2024
Inclusivity in psoriasis trials with Takeda
Fierce Medtech's Fierce 15
[Sponsored] A Person-Centered Approach to Achieving Long-Term Success
CAR-T boxed warnings: What comes next?
Breaking down Eli Lilly’s ESG formula
Gene editing's next act
Create your
podcast in
minutes
It is Free
Pharmacy Podcast Network
Børsen Morgenbriefing
Sarah Westall - Business Game Changers
Startitup podcasty
Wall Street Breakfast